Dermata Therapeutics, Inc.
DRMA
$1.18
-$0.04-3.28%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 824.30K | 874.60K | 1.60M | 1.08M | 909.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.23M | 2.88M | 3.20M | 2.22M | 1.81M |
| Operating Income | -3.23M | -2.88M | -3.20M | -2.22M | -1.81M |
| Income Before Tax | -3.17M | -2.83M | -3.13M | -2.13M | -1.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.17M | -2.83M | -3.13M | -2.13M | -1.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.17M | -2.83M | -3.13M | -2.13M | -1.72M |
| EBIT | -3.23M | -2.88M | -3.20M | -2.22M | -1.81M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.04 | -4.18 | -7.06 | -6.68 | -8.09 |
| Normalized Basic EPS | -1.28 | -2.61 | -4.41 | -4.17 | -5.06 |
| EPS Diluted | -2.04 | -4.18 | -7.06 | -6.68 | -8.09 |
| Normalized Diluted EPS | -1.28 | -2.61 | -4.41 | -4.17 | -5.06 |
| Average Basic Shares Outstanding | 1.55M | 676.60K | 444.10K | 319.60K | 212.50K |
| Average Diluted Shares Outstanding | 1.55M | 676.60K | 444.10K | 319.60K | 212.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
